Recent News

• 11.04.2025 - Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results
• 11.03.2025 - Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition
• 10.31.2025 - Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
• 10.28.2025 - Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025
• 10.17.2025 - Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025
• 10.02.2025 - David Moore
• 10.02.2025 - David Moore
• 10.02.2025 - Corvus Pharmaceuticals Appoints David Moore to Board of Directors
• 10.02.2025 - Corvus Pharmaceuticals Appoints David Moore to Board of Directors
• 10.02.2025 - Corvus Pharmaceuticals Appoints David Moore to Board of Directors

Recent Filings

• 10.17.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 10.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.06.2025 - 3 Initial statement of beneficial ownership of securities
• 10.02.2025 - 8-K Current report
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors